These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37990249)

  • 1. Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis.
    Sun J; Wang S; Ma X; Wei Q; Peng Y; Bai Y; Miao G; Meng C; Liu P
    Eur J Med Res; 2023 Nov; 28(1):536. PubMed ID: 37990249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
    Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
    Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
    Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.
    Albuquerque AM; Eckert I; Tramujas L; Butler-Laporte G; McDonald EG; Brophy JM; Lee TC
    Clin Microbiol Infect; 2023 Jan; 29(1):13-21. PubMed ID: 35863630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
    RECOVERY Collaborative Group
    Lancet; 2022 Jul; 400(10349):359-368. PubMed ID: 35908569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early versus late tracheostomy in critically ill COVID-19 patients.
    Szafran A; Dahms K; Ansems K; Skoetz N; Monsef I; Breuer T; Benstoem C
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015532. PubMed ID: 37982427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
    Trøseid M; Arribas JR; Assoumou L; Holten AR; Poissy J; Terzić V; Mazzaferri F; Baño JR; Eustace J; Hites M; Joannidis M; Paiva JA; Reuter J; Püntmann I; Patrick-Brown TDJH; Westerheim E; Nezvalova-Henriksen K; Beniguel L; Dahl TB; Bouscambert M; Halanova M; Péterfi Z; Tsiodras S; Rezek M; Briel M; Ünal S; Schlegel M; Ader F; Lacombe K; Amdal CD; Rodrigues S; Tonby K; Gaudet A; Heggelund L; Mootien J; Johannessen A; Møller JH; Pollan BD; Tveita AA; Kildal AB; Richard JC; Dalgard O; Simensen VC; Baldé A; de Gastines L; Del Álamo M; Aydin B; Lund-Johansen F; Trabaud MA; Diallo A; Halvorsen B; Røttingen JA; Tacconelli E; Yazdanpanah Y; Olsen IC; Costagliola D;
    Crit Care; 2023 Jan; 27(1):9. PubMed ID: 36627655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis.
    Cherian JJ; Eerike M; Bagepally BS; Das S; Panda S
    Front Pharmacol; 2022; 13():1004308. PubMed ID: 36330085
    [No Abstract]   [Full Text] [Related]  

  • 11. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
    Kalil AC; Patterson TF; Mehta AK; Tomashek KM; Wolfe CR; Ghazaryan V; Marconi VC; Ruiz-Palacios GM; Hsieh L; Kline S; Tapson V; Iovine NM; Jain MK; Sweeney DA; El Sahly HM; Branche AR; Regalado Pineda J; Lye DC; Sandkovsky U; Luetkemeyer AF; Cohen SH; Finberg RW; Jackson PEH; Taiwo B; Paules CI; Arguinchona H; Erdmann N; Ahuja N; Frank M; Oh MD; Kim ES; Tan SY; Mularski RA; Nielsen H; Ponce PO; Taylor BS; Larson L; Rouphael NG; Saklawi Y; Cantos VD; Ko ER; Engemann JJ; Amin AN; Watanabe M; Billings J; Elie MC; Davey RT; Burgess TH; Ferreira J; Green M; Makowski M; Cardoso A; de Bono S; Bonnett T; Proschan M; Deye GA; Dempsey W; Nayak SU; Dodd LE; Beigel JH;
    N Engl J Med; 2021 Mar; 384(9):795-807. PubMed ID: 33306283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia.
    Abizanda P; Calbo Mayo JM; Mas Romero M; Cortés Zamora EB; Tabernero Sahuquillo MT; Romero Rizos L; Sánchez-Jurado PM; Sánchez-Nievas G; Campayo Escolano C; Ochoa Serrano A; Sánchez-Flor Alfaro V; López Bru R; Gómez Ballesteros C; Caldevilla Bernardo D; Callejas González FJ; Andrés-Pretel F; Lauschke VM; Stebbing J
    J Am Geriatr Soc; 2021 Oct; 69(10):2752-2758. PubMed ID: 34235720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
    Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
    Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Adverse Drug Events Observed with Baricitinib 2 mg Versus Baricitinib 4 mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Huang F; Luo ZC
    BioDrugs; 2018 Oct; 32(5):415-423. PubMed ID: 30203252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
    Chen CY; Chen WC; Hsu CK; Chao CM; Lai CC
    Int Immunopharmacol; 2021 Oct; 99():108027. PubMed ID: 34343937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.
    Lin Z; Niu J; Xu Y; Qin L; Ding J; Zhou L
    J Med Virol; 2022 Apr; 94(4):1523-1534. PubMed ID: 34846766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis.
    Manoharan S; Ying LY
    Respir Med; 2022 Oct; 202():106986. PubMed ID: 36150282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.
    Kim MS; An MH; Kim WJ; Hwang TH
    PLoS Med; 2020 Dec; 17(12):e1003501. PubMed ID: 33378357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of baricitinib in critically ill COVID-19 patients.
    Massart N; Fillatre P; Lemaitre F; Mari A; Tron C
    Clin Biochem; 2023 Aug; 118():110601. PubMed ID: 37353137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
    Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.